Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Repligen (RGEN)

Repligen Q1 2025 revenue rises 10% to $169 million; adjusted operating income up 72%

Positive Impact 3 of 5 earnings Written later

Repligen reported first-quarter 2025 revenue of $169 million, up 10% from $153 million, with 14% organic non-COVID growth and adjusted operating income up 72% year over year. The company reiterated its 2025 organic revenue growth guidance of 9.5% to 13.5% and updated full-year guidance to include the acquisition of 908 Devices' bioprocessing portfolio, which it says adds $10 million to revenue.

Key points

  • Q1 revenue $169 million vs. $153 million a year earlier, up 10% as reported and 14% organic non-COVID growth
  • GAAP diluted EPS $0.10 vs. $0.06; adjusted diluted EPS $0.39 vs. $0.30
  • FY2025 guidance: total reported revenue $695 million to $720 million; adjusted diluted EPS $1.63 to $1.72
  • Cash and cash equivalents $697 million at March 31, 2025, down from $757 million at December 31, 2024

The filing

CompanyRepligen (RGEN)
Form8-K, current report
Filed with the SECApr 29, 2025, 7:32 AM ET
Accession number0000950170-25-059569

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 29, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.